Top Suppliers:I want be here


  • DC Chemicals Limited
  • China
  • Product Name: AZD 4017
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

1024033-43-9

1024033-43-9 structure
1024033-43-9 structure
  • Name: AZD 4017
  • Chemical Name: 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid
  • CAS Number: 1024033-43-9
  • Molecular Formula: C22H33N3O3S
  • Molecular Weight: 419.58100
  • Catalog: Research Areas Metabolic Disease
  • Create Date: 2017-11-03 12:33:15
  • Modify Date: 2024-01-02 19:55:21
  • AZD 4017 is a potent, selective 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) inhibitor, with an IC50 of 7 nM.

Name 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid
Synonyms {(3s)-1-[5-(Cyclohexylcarbamoyl)-6-(Propylsulfanyl)pyridin-2-Yl]piperidin-3-Yl}acetic Acid
2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
14M
AZD-4017
Description AZD 4017 is a potent, selective 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) inhibitor, with an IC50 of 7 nM.
Related Catalog
Target

IC50: 7 nM (11β-HSD1)[1].

In Vitro AZD 4017 displays excellent selectivity versus the related enzymes 11-βHSD2, 17β-HSD1, 17β-HSD3 (all IC50>30 μM) and shows no measurable activity against the glucocorticoid and mineralocorticoid receptors. Despite having high potency for the human form of 11β-HSD1, AZD 4017 shows much reduced activity across species with the exception of cynomolgous monkey (IC50=0.029 μM). Additionally, as it is believed that adipose is a key target organ, inhibition of 11β-HSD1 activity is measured in isolated human adipocytes from nondiabetic volunteers. AZD 4017 is shown to be a potent inhibitor in this key target tissue (IC50=0.002 μM) in good agreement with the enzyme potency, thus providing some confidence that AZD 4017 is not restricted from adipose tissue by the fact that it was acidic[1].
In Vivo Since AZD 4017 has lower potency against the mouse enzyme, only a limited number of preclinical pharmacodynamic measurements are performed. Increasing the dose further led to a maximal effect of approximately 70% inhibition at 1500 mg/kg, equivalent to 10×IC50 in the mouse, demonstrating the dose dependent inhibition of 11β-HSD1 by AZD 4017 in this model[1].
References

[1]. Scott JS, et al. Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017). J Med Chem. 2012 Jun 28;55(12):5951-64.

Molecular Formula C22H33N3O3S
Molecular Weight 419.58100
Exact Mass 419.22400
PSA 107.83000
LogP 4.79320

~%

1024033-43-9 structure

1024033-43-9

Literature: Scott, James S.; Bowker, Suzanne S.; Deschoolmeester, Joanne; Gerhardt, Stefan; Hargreaves, David; Kilgour, Elaine; Lloyd, Adele; Mayers, Rachel M.; McCoull, William; Newcombe, Nicholas J.; Ogg, Derek; Packer, Martin J.; Rees, Amanda; Revill, John; Schofield, Paul; Selmi, Nidhal; Swales, John G.; Whittamore, Paul R. O. Journal of Medicinal Chemistry, 2012 , vol. 55, # 12 p. 5951 - 5964

~%

1024033-43-9 structure

1024033-43-9

Literature: Scott, James S.; Bowker, Suzanne S.; Deschoolmeester, Joanne; Gerhardt, Stefan; Hargreaves, David; Kilgour, Elaine; Lloyd, Adele; Mayers, Rachel M.; McCoull, William; Newcombe, Nicholas J.; Ogg, Derek; Packer, Martin J.; Rees, Amanda; Revill, John; Schofield, Paul; Selmi, Nidhal; Swales, John G.; Whittamore, Paul R. O. Journal of Medicinal Chemistry, 2012 , vol. 55, # 12 p. 5951 - 5964

~%

1024033-43-9 structure

1024033-43-9

Literature: Scott, James S.; Bowker, Suzanne S.; Deschoolmeester, Joanne; Gerhardt, Stefan; Hargreaves, David; Kilgour, Elaine; Lloyd, Adele; Mayers, Rachel M.; McCoull, William; Newcombe, Nicholas J.; Ogg, Derek; Packer, Martin J.; Rees, Amanda; Revill, John; Schofield, Paul; Selmi, Nidhal; Swales, John G.; Whittamore, Paul R. O. Journal of Medicinal Chemistry, 2012 , vol. 55, # 12 p. 5951 - 5964

~%

1024033-43-9 structure

1024033-43-9

Literature: Scott, James S.; Bowker, Suzanne S.; Deschoolmeester, Joanne; Gerhardt, Stefan; Hargreaves, David; Kilgour, Elaine; Lloyd, Adele; Mayers, Rachel M.; McCoull, William; Newcombe, Nicholas J.; Ogg, Derek; Packer, Martin J.; Rees, Amanda; Revill, John; Schofield, Paul; Selmi, Nidhal; Swales, John G.; Whittamore, Paul R. O. Journal of Medicinal Chemistry, 2012 , vol. 55, # 12 p. 5951 - 5964